Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,613.50
Bid: 1,613.50
Ask: 1,614.50
Change: -3.00 (-0.19%)
Spread: 1.00 (0.062%)
Open: 1,619.50
High: 1,620.50
Low: 1,610.50
Prev. Close: 1,616.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up UPDATE

Mon, 22nd Apr 2013 07:20

Admiral Group: Deutsche Bank takes target price from 1140p to 1300p retaining a hold recommendation.African Barrick Gold: Deutsche Bank ups target price from 173p to 180p staying with its hold recommendation.Albemarle & Bond: Canaccord Genuity reduces target price from 280p to 146p and downgrades from a speculative buy to hold.Anglo American: Deutsche Bank cuts target price from 2210p to 2170p, while its buy recommendation remains unaltered. HSBC Holdings moves target price from 2240p to 2250p and maintains an overweight rating.Antofagasta: HSBC Holdings moves target price from 1160p to 1080p and reiterates a neutral rating.AstraZeneca: Credit Suisse increases target price from 3050p to 3130p and maintains an underperform rating.BHP Billiton: HSBC Holdings reduces target price from 2250p to 2110p, while upgrading to overweight. Espirito Santo cuts target price from 1703p to 1605p, while upgrading to neutral.Brooks Macdonald: Canaccord Genuity revises target price from 1540p to 1620p keeping a buy recommendation.Brown (N) Group: HSBC Holdings takes target price from 430p to 485p and retains an overweight rating.Burford Capital: Espirito Santo revises target price from 149p to 140p and stays with its buy recommendation.Cable & Wireless Communications: Jefferies shifts target price from 40p to 42p and retains a hold recommendation.Chariot Oil & Gas: UBS cuts target price from 70p to 20p downgrading from buy to neutral.Electrocomponents: Goldman Sachs reduces target price from 311p to 277p and downgrades to neutral.Eurasian Natural Resources: Exane BNP raises target price from 270p to 320p staying with a neutral rating.GlaxoSmithKline: Credit Suisse increases target price from 1450p to 1670p and reiterates its neutral rating.Hansteen Holdings: Espirito Santo lowers target price from 76p to 85p maintaining a neutral rating.Ithaca Energy: Westhouse Securities ups target price from 165p to 200p and reiterates a buy recommendation. RBC Capital increases target price to 225p and keeps an outperform rating.Kazakhmys: Credit Suisse upgrades from underperform to neutral with its target price at 450p. Exane BNP increases target price from 350p to 390 upgrading to neutral.Legal & General Group: Deutsche Bank ups target price from 170p to 189p keeping a buy recommendation.Lloyds Banking Group: RBC Capital shifts target price from 69p to 65p and reiterates an outperform rating.NetDimensions: Sanlam Securities restarts with a target price of 80p and a buy recommendation.New World Resources: Exane BNP cuts target price from 180p to 165p and leaves its underperform rating unchanged.Premier Farnell: Goldman Sachs lowers target price from 240p to 226p and downgrades to neutral.Prudential: Deutsche Bank increases target price from 1060p to 1240p maintaining its buy recommendation.Reckitt Benckiser: Canaccord Genuity takes target price from 3425p to 4100p, but still recommends selling.Regus: JP Morgan shifts target price from 135p to 140p, while downgrading to underweight.Rentokil Initial: Deutsche Bank moves target price from 76p to 100p reiterating a hold recommendation.Resolution: Deutsche Bank lowers target price from 285p to 273p and keeps a hold recommendation.Rio Tinto: HSBC Holdings cuts target price from 4180p to 4160p, while its overweight rating remains unchanged. Espirito Santo raises target price from 2910p to 3160p and upgrades to neutral.Sagentia Group:Westhouse Securities downgrades from add to neutral with a target price of 107p.Segro: Espirito Santo shifts target price from 247p to 250p and leaves its neutral rating unchanged.Spectris: Goldman Sachs cuts target price from 3250p to 2850p maintaining a strong buy recommendation. Credit Suisse reduces target price from 2670p to 2350p and retains an outperform rating. UBS takes target price from 2700p to 2500p, while leaving its buy recommendation unchanged. Bank of America moves target price from 2080p to 1980p and keeps an underperform rating. JP Morgan reduces target price from 2575p to 2455p, while its overweight rating remains unchanged.Spirent Communications: Jefferies reduces target price from 196p to 140p keeping a buy recommendation. Investec places its target price (prev. 175p) under review reiterating its buy recommendation. Canaccord Genuity lowers target price from 135p to 120p and retains a hold recommendation.St James's Place: Deutsche Bank raises target price from 485p to 525p, while keeping a hold recommendation.Sweett Group: WH Ireland shifts target price from 27p to 33p and moves from a speculative buy to a buy rating.Talk Talk Telecom: Jefferies moves target price from 270p to 284p and maintains a buy recommendation. Credit Suisse raises target price from 200p to 275p and retains an outperform rating.Travis Perkins: Goldman Sachs downgrades from strong buy to buy with a target price of 1708p.Vedanta Resources: HSBC Holdings reduces target price from 1310p to 1280p and maintains its neutral rating.Vodafone Group: Jefferies shifts target price from 174p to 179p keeping a hold recommendation.Whitbread: Credit Suisse increases target price from 2760p to 2900p reiterating an outperform rating.William Hill: Nomura shifts target price from 333p to 339p and stays with its reduces rating. JP Morgan moves target price from 485p to 490p keeping an overweight rating.
More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.